FDA approve vibegron for overactive bladder

Vibegron is an oral β3 agonist. Approval was based on a development program involving over 4,000 patients with overactive bladder including the phase 3 EMPOWUR study. A market authorisation application has not yet been submitted to the EMA.

Source:

Biospace Inc.